SAGE Therapeutics (SAGE) Stock Rating Lowered by BidaskClub

BidaskClub downgraded shares of SAGE Therapeutics (NASDAQ:SAGE) from a sell rating to a strong sell rating in a research report released on Friday, July 27th.

SAGE has been the subject of several other reports. LADENBURG THALM/SH SH began coverage on shares of SAGE Therapeutics in a report on Wednesday, June 6th. They set a buy rating and a $230.00 target price for the company. Cowen restated a buy rating on shares of SAGE Therapeutics in a report on Thursday, May 3rd. ValuEngine upgraded shares of SAGE Therapeutics from a hold rating to a buy rating in a report on Monday, April 2nd. Morgan Stanley boosted their price objective on shares of SAGE Therapeutics from $225.00 to $228.00 and gave the stock an overweight rating in a report on Friday, July 13th. Finally, Canaccord Genuity reaffirmed a buy rating and issued a $220.00 target price on shares of SAGE Therapeutics in a research report on Tuesday, June 12th. Two analysts have rated the stock with a sell rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. SAGE Therapeutics has a consensus rating of Buy and an average target price of $199.19.

SAGE Therapeutics traded up $0.96, hitting $148.36, during trading hours on Friday, Marketbeat reports. 233,107 shares of the stock traded hands, compared to its average volume of 394,225. SAGE Therapeutics has a one year low of $59.57 and a one year high of $195.97.

SAGE Therapeutics (NASDAQ:SAGE) last released its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.84) by $1.48. The business had revenue of $90.00 million for the quarter. analysts forecast that SAGE Therapeutics will post -7.86 earnings per share for the current year.

Several hedge funds have recently modified their holdings of SAGE. US Bancorp DE boosted its holdings in SAGE Therapeutics by 5,593.3% in the 2nd quarter. US Bancorp DE now owns 854 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 839 shares during the period. Creative Planning bought a new position in SAGE Therapeutics in the 2nd quarter worth $210,000. Atria Investments LLC bought a new position in SAGE Therapeutics in the 2nd quarter worth $218,000. Tiverton Asset Management LLC bought a new position in SAGE Therapeutics in the 2nd quarter worth $229,000. Finally, World Asset Management Inc bought a new position in SAGE Therapeutics in the 2nd quarter worth $252,000.

About SAGE Therapeutics

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).

Recommended Story: Google Finance Portfolio Workaround

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply